seizure period. In contrast, the CPT group has the shortest active seizure period, but often presents with SE. The most characteristic clinical manifestation, occurring in all patients, is the ictal vomiting. In PS a genetic predisposition to seizures is common. The outlook is generally good, with seizure remission before 12 years of age.
EFFECT OF METHYLPHENIDATE IN ADHD WITH EPILEPSY OR WITH EEG ABNORMALITIES WITHOUT SEIZURES
The safety and efficacy of methylphenidate (MPH) in the treatment of ADHD, group 1) with epilepsy and group 2) with EEG abnormalities without seizures, were determined in a study of 119 children (98 males, 21 females; ages 6 to 16 years) at Gazi University, Ankara, Turkey. The neuroiogic examination showed only soft signs in 8% of patients. Brain scans, vision and hearing were normal, and WISC-R scores were average (mean 92.3 +/-0.2). Of 57 patients with epilepsy, 34 had complex partial seizures, 13 had tonic-clonic seizures, and 10 had multiple seizures; 52 received antiepileptic (AED) monotherapy and 5 polytherapy. At the end of the 12 month period of AED with added MPH (0.3-1 mg/kg/day) treatment, the mean yearly seizure frequency was unchanged (8.2 pre-MPH treatment and 8.1 post-treatment), but 5 (10%) patients had an increase in seizures. None of the 62 patients with ADHD and EEG abnormalities developed seizures during treatment with MPH (without AED). Percentage of patients with EEG epileptiform activity was decreased in both the ADHD+epilepsy group and the ADHD without seizure group; 35.1% at baseline cf 19.3% post-treatment (p=0.01) and 24.2% cf 12.9% (p=0.02), respectively. The baseline and the last mean total ADHD and Conners' scores from parents' and teachers' questionnaires showed significant improvements in both the epileptic and the abnormal EEG groups. On clinician ratings, 92 of the 119 children in the study showed reduced ADHD symptoms, and only 9 patients had deterioration in behavior, 6 of whom were epileptic. Side effects of MPH were observed in 26 (22%) patients and included loss of appetite (23) 
CLASSIFICATION, DIAGNOSIS, AND TREATMENT OF SYNCOPE
The classification, diagnosis, investigation, and management of syncopal attacks in childhood are reviewed from the Department of Cardiology, Royal Hospital for Sick Children, Glasgow, UK. The causes of childhood syncope are classified in three groups: neurally mediated, cardiovascular, and noncardiovascular pseudo-syncope. Neurallymediated (neurocardiogenic) syncopes are most commonly reflex in type, and consist of a transient disturbance in the autonomic control of heart rate and blood pressure. They occur at any age, typically in toddlers and in children between 9 and 14 years of age. Characteristically, the child is either sitting or standing, and suffers loss of tone and consciousness, preceded by dizziness, nausea, and pallor. Hypotension and/or bradycardia result in cerebral hypoxia, and when severe, an anoxic seizure and incontinence. The reflex anoxic seizure resembles a pallid breath-holding attack in a toddler, and consists of opisthotonus and twitching. Unlike an epileptiform discharge, the electroencephalographic (EEG) record is flat during a reflex anoxic seizure. 
